Taking stock of the drug industry, from the lab to the medicine chestNovember 12, 2024Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Mario Tama/Getty Images STAT+ | Johnson & Johnson sues Biden administration over payment terms for 340B hospitals J&J recently sought to change 340B payment terms for its Xarelto blood thinner and the Stelara plaque psoriasis treatment. By Ed Silverman STAT+ | AstraZeneca, Daiichi Sankyo change strategy on closely watched cancer drug AstraZeneca and partner Daiichi Sankyo said they had filed for approval in a different lung cancer indication. By Andrew Joseph STAT+ | Despite setback, AbbVie's big bet on neuroscience has yet to play out The company isn't ready to give up on emraclidine yet — and it has other neuroscience drugs in its pipeline that could show potential soon. By Elaine Chen Emma McIntyre/Getty Images for MAKERS STAT+ | The end of 23andMe's drug discovery dream The genetics startup announced it would lay off 40% of its workforce and halt its efforts to develop new medicines, once a cornerstone of its strategy. By Matthew Herper STAT+ | Fueled by a 'fall off your chair' discovery and $101 million, Trace launches to take on ALS Trace Neuroscience, armed with $101 million in funding, is developing a drug targeting UNC13A, a gene linked to amyotrophic lateral sclerosis By Jonathan Wosen More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2024, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments